Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALKS
Previous Symbol
CUSIPG0176710
Phone353-1772-8000
Debt
Debt-to-Equity Ratio0.24
Current Ratio2.85
Quick Ratio2.56
Price-To-Earnings
Trailing P/E Ratio-88.70
Forward P/E Ratio-65.64
P/E GrowthN/A
Sales & Book Value
Annual Sales$903.37 million
Price / Sales5.65
Cash Flow$0.2679 per share
Price / Cash Flow122.49
Book Value$7.82 per share
Price / Book4.20
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-157,940,000.00
Net Margins-13.23%
Return on Equity-0.12%
Return on Assets-0.08%
Miscellaneous
Employees2,000
Outstanding Shares155,380,000
Market Cap$5.25 billion
OptionableOptionable
Alkermes (NASDAQ:ALKS) Frequently Asked Questions
What is Alkermes' stock symbol?
Alkermes trades on the NASDAQ under the ticker symbol "ALKS."
How were Alkermes' earnings last quarter?
Alkermes Plc (NASDAQ:ALKS) released its earnings results on Tuesday, October, 23rd. The company reported $0.07 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.15. The firm earned $248.72 million during the quarter, compared to analysts' expectations of $236.70 million. Alkermes had a negative return on equity of 0.12% and a negative net margin of 13.23%. The company's revenue was up 14.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.03 EPS. View Alkermes' Earnings History.
When is Alkermes' next earnings date?
What guidance has Alkermes issued on next quarter's earnings?
Alkermes updated its FY18 earnings guidance on Tuesday, October, 23rd. The company provided earnings per share guidance of $0.12-0.31 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.09. The company issued revenue guidance of $1.015-1.045 billion, compared to the consensus revenue estimate of $1.02 billion.
What price target have analysts set for ALKS?
13 analysts have issued twelve-month target prices for Alkermes' shares. Their predictions range from $31.00 to $66.00. On average, they anticipate Alkermes' stock price to reach $49.4167 in the next twelve months. This suggests a possible upside of 50.6% from the stock's current price. View Analyst Price Targets for Alkermes.
What is the consensus analysts' recommendation for Alkermes?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 3 sell ratings, 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alkermes.
What are Wall Street analysts saying about Alkermes stock?
Here are some recent quotes from research analysts about Alkermes stock:
- 1. According to Zacks Investment Research, "Alkermes exceeded earnings and sales estimates in the third quarter of 2018. The company’s Vivitrol and Aristada continue to drive growth for the company. The company also raised its revenue and earnings guidance for 2018. This year, Alkermes’ development pipeline will witness key events like the upcoming regulatory interactions for ALKS 5461 for the adjunctive treatment of major depressive disorder and the ALKS 3831 ENLIGHTEN-2 pivotal study data in schizophrenia. The Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee jointly voted that the benefit-risk profile was not adequate to support approval of ALKS 5461. The launch of Aristada Initio during the third quarter has been encouraging. It further distinguishes the company’s position in the market and provides an opportunity to address unmet patient need. However, Alkermes is highly dependent on manufacturing and/or royalty revenue" (11/12/2018)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate the Neutral rating for ALKS stock and are reducing our PT by $5 to $41. We believe the FDA advisory panel view of the ALKS-5461 NDA is a major setback not only for the drug but also to the ability of ALKS to convince investors that the company can develop proprietary therapies of meaningful commercial potential." (11/5/2018)
Has Alkermes been receiving favorable news coverage?
Press coverage about ALKS stock has been trending somewhat positive on Saturday, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alkermes earned a daily sentiment score of 1.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Alkermes' key competitors?
Some companies that are related to Alkermes include Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS).
Who are Alkermes' key executives?
Alkermes' management team includes the folowing people:
- Mr. Richard F. Pops, Chairman & CEO (Age 56)
- Dr. Floyd E. Bloom, Co-Founder & Director (Age 81)
- Mr. James M. Frates, Sr. VP, CFO & Treasurer (Age 51)
- Mr. James A. Robinson Jr., Pres & COO (Age 48)
- Mr. Iain Michael Brown, Sr. VP of Fin. & Chief Accounting Officer (Age 49)
Who are Alkermes' major shareholders?
Alkermes' stock is owned by a number of of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (14.98%), FMR LLC (14.64%), Vanguard Group Inc (8.51%), Vanguard Group Inc. (8.51%), BlackRock Inc. (6.41%) and Franklin Resources Inc. (2.75%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Elliot Ehrich, Floyd E Bloom, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Laurie Keating, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Institutional Ownership Trends for Alkermes.
Which institutional investors are selling Alkermes stock?
ALKS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Mitsubishi UFJ Trust & Banking Corp, Deutsche Bank AG, Primecap Management Co. CA, Credit Suisse AG, Eaton Vance Management, Andra AP fonden and Swiss National Bank. Company insiders that have sold Alkermes company stock in the last year include David W Anstice, Floyd E Bloom, Iain Michael Brown, James M Frates, Laurie Keating, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops and Shane Cooke. View Insider Buying and Selling for Alkermes.
Which institutional investors are buying Alkermes stock?
ALKS stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, First Manhattan Co., Pictet Asset Management Ltd., Franklin Resources Inc., Vanguard Group Inc, Vanguard Group Inc., Korea Investment CORP and Skandinaviska Enskilda Banken AB publ. View Insider Buying and Selling for Alkermes.
How do I buy shares of Alkermes?
Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alkermes' stock price today?
One share of ALKS stock can currently be purchased for approximately $32.82.
How big of a company is Alkermes?
Alkermes has a market capitalization of $5.25 billion and generates $903.37 million in revenue each year. The company earns $-157,940,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Alkermes employs 2,000 workers across the globe.
What is Alkermes' official website?
How can I contact Alkermes?
Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]
MarketBeat Community Rating for Alkermes (NASDAQ ALKS)
MarketBeat's community ratings are surveys of what our community members think about Alkermes and other stocks. Vote "Outperform" if you believe ALKS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALKS will underperform the S&P 500 over the long term. You may vote once every thirty days.
